Tuesday, October 14, 2025 11:21:06 AM
This weeks trading action is the same as 100 other weeks. There is very close monitoring, by shorts/those interested in controlling our stock, of Anavex’s PR’s before financial or medical conferences. This is true of the clock stops and any other points in time up to EMA approval. This is widely known that companies do NOT risk influencing/risking their application process and or bringing about a lawsuit during this time period. On top of that everyone knows Dr. Missling is very conservative in nature as a leader, good or bad.
All this said it really speaks volumes as to the desperateness of shorts continuing a weak narrative correlation at moments in weakness of the stock price trying to scare retail. This is why it is very important imo to not try and be the 1rst poster, for the 52nd trying to predict the beginning of the next run up in price. It either is a case of drmrntia setting in or it almost appears to be in collusion by longs trying to pull in new money so the shorts have “food” to harvest along the way.
Put the phone down, step away from the computer, get outside and take a few deep breaths on a nature walk. If it was shared with us by a doctor that our life would end tomorrow, what would be most important to us? That is what is truly needing our focus. Before we know it Christmas will be here!
Cheers
Tred
All this said it really speaks volumes as to the desperateness of shorts continuing a weak narrative correlation at moments in weakness of the stock price trying to scare retail. This is why it is very important imo to not try and be the 1rst poster, for the 52nd trying to predict the beginning of the next run up in price. It either is a case of drmrntia setting in or it almost appears to be in collusion by longs trying to pull in new money so the shorts have “food” to harvest along the way.
Put the phone down, step away from the computer, get outside and take a few deep breaths on a nature walk. If it was shared with us by a doctor that our life would end tomorrow, what would be most important to us? That is what is truly needing our focus. Before we know it Christmas will be here!
Cheers
Tred
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2026 10:15:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
